New strategy to build a healthier market for childhood cancer medicines - World Health Organization (WHO)

ViiV Healthcare press releaseViiV Healthcare announced an agreement appointing Axmed as a non-exclusive distributor to enable procurement and supply of ViiV Healthcare HIV medicines in more than 50 middle-income countries, subject to applicable local regulatory requirements. This agreement aims to offer a simpler route to access more choice in HIV care to support countries’ HIV response. Axmed is a technology-enabled business-to-business platform that connects healthcare procurers in low- and middle-income countries with suppliers to provide access to medicines. Through their technological solutions, local governments and healthcare institutions in these countries will be able to lower procurement costs and deliver efficient logistics supporting their healthcare systems to stretch resources further and reach more people. Read the full press release here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.